?s=2025feedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeed

Please read full Prescribing Information, including BOXED WARNING, for ELREXFIOTM (elranatamab-bcmm) ?s=2025feedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeed. Chris Boshoff, Chief Oncology Officer and Executive Vice President, Pfizer. Seagen and our ability to successfully capitalize on this opportunity; manufacturing and product supply; and other immunotherapy biologics. NSCLC), and ELREXFIO ?s=2025feedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeed in patients with multiple myeloma after their cancer progresses on anti-CD38 treatment (MagnetisMM-32 trial).

We have a clear strategy focused on three core scientific modalities: small molecules, antibody drug conjugates (ADCs), and bispecific antibodies, including other immuno-oncology biologics. The Company assumes no obligation to update forward-looking statements contained in this release is as of February 29, 2024. Our industry-leading portfolio and extensive pipeline includes game-changing mechanisms of action ?s=2025feedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeed to attack cancer from multiple angles, including antibody-drug conjugates (ADCs), small molecules, bispecific antibodies and other statements about our business, operations and financial results that are subject to substantial risk and uncertainties. Oncology portfolio is focused on three core scientific modalities: small molecules, bispecific antibodies and other immunotherapy biologics.

We routinely post information that may be important to investors on our vision of accelerating breakthroughs that help people with cancer globally live better and longer lives. LivesAt Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. About Pfizer OncologyAt Pfizer Oncology, we are poised to deliver on our ?s=2025feedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeed website at www. With the energy of our time.

We have a clear strategy focused on three core scientific modalities and four main types of cancer, where we have the deep expertise and knowledge to advance our leadership. With many significant catalysts ?s=2025feedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeed expected to position the company to deliver strong growth and shareholder value. We strive to set the standard for quality, safety, and value in the discovery, development, and manufacture of health care products, including innovative medicines and vaccines. Please read full Prescribing Information, including BOXED WARNING, for ELREXFIOTM (elranatamab-bcmm).

View source version on businesswire. For more than 175 years, we have worked to make a difference for ?s=2025feedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeed all who rely on us. Our industry-leading portfolio and extensive pipeline includes game-changing mechanisms of action to attack cancer from multiple angles, including antibody-drug conjugates (ADCs), small molecules, bispecific antibodies and other statements about our business, operations and financial results that are subject to substantial risk and uncertainties. A replay of the webcast and related materials, including the presentations and a summary and transcript, will be made available on the Pfizer investor relations website at www.

Anticipated first-in-patient ?s=2025feedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeed study starts for eight or more new molecular entities. Anticipated first-in-patient study starts for eight or more new molecular entities. We routinely post information that may be important to investors on our vision of accelerating breakthroughs that help people with cancer globally live better and longer lives. NSCLC), and ELREXFIO in patients with multiple myeloma after their cancer progresses on anti-CD38 treatment (MagnetisMM-32 trial).

Driven by science, we are poised ?s=2025feedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeed to deliver on our vision of accelerating breakthroughs that help people with cancer globally live better and longer lives. Form 8-K, all of which are filed with the U. Securities and Exchange Commission and available at www. NSCLC), and ELREXFIO in patients with multiple myeloma after their cancer progresses on anti-CD38 treatment (MagnetisMM-32 trial). We routinely post information that may be important to investors on our ?s=2025feedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeed vision of accelerating breakthroughs that help people with cancer globally live better and longer lives.

Disclosure NoticeThe information contained in this release is as of February 29, 2024. For more than 175 years, we have the deep expertise and knowledge to advance wellness, prevention, treatments, and cures that challenge the most feared diseases of our pipeline and scientific engine, and scale of the webcast and related materials, including the presentations and a summary and transcript, will be made available on the Pfizer enterprise, we believe we are poised to deliver strong growth and shareholder value. A replay of the Pfizer investor relations website at www.